XML 45 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 01, 2017
USD ($)
Apr. 02, 2015
USD ($)
Oct. 31, 2013
USD ($)
Mar. 31, 2017
USD ($)
item
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jun. 30, 2016
USD ($)
Apr. 30, 2016
USD ($)
Sep. 09, 2014
USD ($)
Summary Of Significant Accounting Policies                    
Number of product candidates under clinical development | item       1            
Royalty and milestone payments received     $ 240,500              
Use of Estimates                    
Cash discount (as a percent)       2.00%            
Discount reimbursement period after filling of prescription subject to discount       1 month            
Recently Issued Accounting Standards                    
Benefit from income taxes       $ 202 $ (5,994)          
Other assets, long-term       1,432   $ 1,458        
Convertible Notes       256,774   252,725        
Senior Notes       $ 366,653   466,051        
ASU 2016-09                    
Recently Issued Accounting Standards                    
Accumulated deficit $ (300)                  
Deferred tax assets related to share-based compensation           5,800        
Valuation allowance for deferred tax assets           5,800        
Minimum                    
Use of Estimates                    
Discount taken off period after the quarter in which product shipped to the customer       1 month            
Period after the quarter in which prescription is filled for paying rebate       2 months            
Minimum | Managed Care Rebates                    
Use of Estimates                    
Period after the quarter in which prescription is filled for rebate       1 month            
Minimum | Medicare Part D Coverage Gap Rebates                    
Use of Estimates                    
Period after the quarter in which prescription is filled for rebate       2 months            
Maximum                    
Use of Estimates                    
Product return period prior to expiration       6 months            
Period after expiration for accepting unsalable product       12 months            
Discount taken off period after the quarter in which product shipped to the customer       2 months            
Period after the quarter in which prescription is filled for paying rebate       3 months            
Maximum | Managed Care Rebates                    
Use of Estimates                    
Period after the quarter in which prescription is filled for rebate       3 months            
Maximum | Medicare Part D Coverage Gap Rebates                    
Use of Estimates                    
Period after the quarter in which prescription is filled for rebate       3 months            
NUCYNTA ER, NUCYNTA and Gralise                    
Use of Estimates                    
Rebate claim               $ 5,700    
Rebates       $ 4,700   1,000        
NUCYNTA ER | Minimum                    
Use of Estimates                    
Product shelf-life       24 months            
NUCYNTA ER | Maximum                    
Use of Estimates                    
Product shelf-life       36 months            
NUCYNTA                    
Use of Estimates                    
Product shelf-life       36 months            
Gralise | Minimum                    
Use of Estimates                    
Product shelf-life       24 months            
Gralise | Maximum                    
Use of Estimates                    
Product shelf-life       36 months            
CAMBIA | Minimum                    
Use of Estimates                    
Product shelf-life       24 months            
CAMBIA | Maximum                    
Use of Estimates                    
Product shelf-life       48 months            
Zipsor                    
Use of Estimates                    
Product shelf-life       36 months            
Lazanda | Minimum                    
Use of Estimates                    
Product shelf-life       24 months            
Lazanda | Maximum                    
Use of Estimates                    
Product shelf-life       36 months            
Convertible Notes                    
Summary Of Significant Accounting Policies                    
Aggregate principal amount of notes issued       $ 345,000   345,000       $ 345,000
Recently Issued Accounting Standards                    
Convertible Notes                   $ 226,000
Senior Notes       256,774   252,725        
Senior Notes                    
Summary Of Significant Accounting Policies                    
Aggregate principal amount of notes issued   $ 575,000   475,000         $ 375,000  
Proceeds from the issuance of debt   $ 562,000                
Recently Issued Accounting Standards                    
Senior Notes       $ 466,653   $ 466,051        
Payments of Debt Issuance Costs             $ 500